Since serum ANGPTL2 levels were significantly increased in patients with non-small cell lung cancer, it could serve as a novel potential diagnostic and prognostic biomarker (Chen et al., 2017). This evidence concerns the gene ANGPTL2 and non-small cell lung carcinoma.